China National Biotec Group

China National Biotec Group (CNBG) is a research-driven biotech company that discovers, develops, manufactures and markets a broad range of human health products, including vaccines, blood derivatives, biopharmaceuticals, diagnostic reagents and others.  The company is also a major player in China for the import and export of scientific and medical equipment and materials.

CNBG is a state-owned company that works under the State-owned Assets Supervision and Administration Commission of State Council SASAC of People’s Republic of China. The company consists of 6 Institutes of Biological Products, which were formerly under the Ministry of Health, in Beijing CNBG NVSI, CNBG TiantanBio, Changchun CNBG Changchun Institute, Chengdu CNBG Chengdu Institute, Lanzhou CNBG Lanzhou Institute, Shanghai CNBG Shanghai Institute, Wuhan CNBG Wuhan Institute, and a international trading company in Beijing CNBG CSIMC. Headquartered in Beijing, CNBG's operation has been mainly focused in China while in the recent years has been expanded into the international markets through its trading subsidiaries and business partners. With more than 9,000 employees and worldwide revenues of 421 million USD in 2006, CNBG is the largest producer of vaccines and blood derivatives in China, enjoying more than 80% and 30% market share respectively. CNBG produced over 1 billion doses of vaccines in 2006 and is among top 10 vaccine companies in the world. CNBG has 13 principal manufacturing sites strategically located in 6 cities around China. All manufacturing lines of CNBG have been granted with cGMP certificates from State Food and Drug Administration (SFDA) of China. The state-of-the-arts manufacturing facilities enable CNBG to expand into international markets as well as to be a ideal contracted manufacturer for business partners around the world.

Updated - CNBG - All Rights Reserved